

Groundbreaking Prostate Cancer Treatments Deliver Hope



The Prostate Cancer Research Program (PCRP), part of the Congressionally Directed Medical Research Programs (CDMRP) at the Department of Defense, is one of the most effective programs in the world designed to produce treatments and, one day, a cure for prostate cancer.



XGEVA® is used for prostate cancer patients with metastatic bone disease to prevent fractures, severe bone pain, and spinal cord compression.




ZYTIGA® is a prescription medicine that is used along with prednisone. ZYTIGA® is used to treat men with prostate cancer that has spread to other parts of the body.



A prescription medicine used to treat prostate cancer that no longer responds to a hormone therapy or surgical treatment to lower testosterone OR has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone.



An AR-targeted therapy indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer.



Identifies whether your tumor will respond to AR-targeted therapies—or whether you should consider chemotherapy or other therapies.



RUBRACA® tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone).



Tell your elected officials that you want increased funding for the PCRP to generate more new treatment options for prostate cancer patients. Visit zerocancer.org/advocacy to get started today.

ZERO
THE END OF PROSTATE CANCER